Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial
Elisa Fontana(Sarah Cannon Research Institute), Anguraj Sadanandam(Institute of Cancer Research), Sanna Hulkki-Wilson(Institute of Cancer Research), Mirella Giordano(University of Pisa), Maggie C.U. Cheang(Institute of Cancer Research), Chanthirika Ragulan(Royal Marsden NHS Foundation Trust), Katherine Eason(University of Cambridge), Patrick Varun Lawrence(Institute of Cancer Research), Livio Trusolino(University of Turin), David Cunningham(Royal Marsden NHS Foundation Trust), Timothy Price(Basil Hetzel Institute), Gift Nyamundanda(Institute of Cancer Research), Dongsheng Tu(Ontario Institute for Cancer Research), Derek J. Jonker(University of Ottawa), Jonathan M. Loree(University of British Columbia), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Francesco Sclafani(Royal Marsden NHS Foundation Trust), Filippo Pietrantonio(Fondazione IRCCS Istituto Nazionale dei Tumori), Chiara Cremolini(University of Pisa), Ruwaida Begum, Jeremy Shapiro(Cabrini Hospital), Paul Waring(The University of Melbourne), Lillian L. Siu(University Health Network), Christopher J. O’Callaghan(Queen's University), Naureen Starling(Royal Marsden NHS Foundation Trust)
Cited by 7
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k